Almac Sciences Adds Biologics Testing to its Analytical Solutions Suite

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter 10-07-2020
Volume 15
Issue 10

With a recent expansion, Almac will now have the ability to include enhanced analytical method development and bioanalytical testing.

Almac Sciences, a member of the Almac Group, is undergoing expansion to add biologics testing to its suite of analytical solutions.

The expansion will include current good manufacturing practice (CGMP) lot release and stability testing, fit-for-purpose analytical method development, phase-appropriate method validation, and raw material testing for microbial and mammalian expression systems.

“Biologics have gained huge traction in the last decade and are poised for stronger growth in the coming years with potential to significantly impact patient lives,” said Dr. John Robson, vice-president, Analytical Operations, Almac Sciences, in a Sept. 24, 2020 company press release. “The launch of this service offering furthermore demonstrates Almac’s commitment to offering a best-in-class service to our global client base and in advancing human health. We are confident the addition of biologics testing solutions will continue to strengthen our competitive position in the marketplace.”

Source: Almac​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Articles in this issue
Restructuring Method Transfer Throughout Global Sites
Restructuring Method Transfer Throughout Global Sites
Darren Baker/Stock.Adobe.com - scientist observing test tube
When Assessing Protein Aggregation Grows Increasingly Challenging
Almac Sciences Adds Biologics Testing to its Analytical Solutions Suite
PharmaLex Group Completes Merger with BioStat Solutions
Natoli Installs Tablet Press at its New Research and Training Facility
Thermo Fisher to Invest More than $140 Million into its Lab Plastics Consumables for COVID-19 Testing
Sai Life Sciences’ Screening Capabilities Enhanced with Expanded Cellular Analysis Platforms
StarBright Violet 515 Dye from Bio-Rad Enhances Flow Cytometry
Paradigm4’s Single Cell App Allows for Analysis of Large-Scale Datasets
CytoSMART Technologies’ New Automated Live-Cell Imaging System Keeps Lab Teams Coordinated
Promega’s New Capillary Electrophoresis Instrument Enhances Benchtop Analysis
Aigenpulse’s Data Analysis Suite Automates Flow Cytometry
Recent Videos
Industry Outlook 2025: Political Impacts on Supply Chains
Industry Outlook 2025: Political Impacts on Supply Chains
Industry Outlook 2025: Business Viability and Global Collaboration
Industry Outlook 2025: Business Viability and Global Collaboration
Industry Outlook 2025: Large Language Models
Industry Outlook 2025: Large Language Models
Safe, Smart, and Sustainable Packaging for the Healthcare Industry
Safe, Smart, and Sustainable Packaging for the Healthcare Industry
Drug Digest: Strategic Partnerships
Drug Digest: Strategic Partnerships
Ask the Expert: Product Inspection, Part Two; Automated Product Inspection and Cold Chain Considerations
Ask the Expert: Product Inspection, Part Two; Automated Product Inspection and Cold Chain Considerations
Behind the Headlines: Episode 13; Budget Cuts, Reshoring, and Biotech Buyouts
Behind the Headlines: Episode 13; Budget Cuts, Reshoring, and Biotech Buyouts
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Industry Outlook 2025: Continuing Innovation
DCAT Week 2025: Key Ingredients in Pharmaceutical Manufacturing
DCAT Week 2025: Key Ingredients in Pharmaceutical Manufacturing
DCAT Week 2025: Industry Need for Continuous Biologics Manufacturing
DCAT Week 2025: Industry Need for Continuous Biologics Manufacturing
Related Content
INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

Patrick Lavery;Feliza Mirasol
April 1st 2025
Article

William Wainwright, business development manager at Iwata Label USA, discusses the practical security benefits of functional labels at INTERPHEX 2025.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Culture Biosciences Opens INTERPHEX 2025 with Launch of Cloud-Integrated Mobile Bioreactor

Patrick Lavery
April 1st 2025
Article

The company said the Stratyx 250 is the first bioreactor of its kind to offer biotech companies a combination of automation, remote process control, and flexibility.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Facing the Latest Patent Cliff

Mike Hennessy Jr.
April 1st 2025
Article

Over the course of the next five years, the bio/pharma industry is expected to see the patents of multiple blockbuster drugs expire, impacting some key industry players.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.